AbCellera Biologics Second Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag

AbCellera Biologics (NASDAQ:ABCL) Second Quarter 2024 Results

Key Financial Results

• Revenue: US$7.32m (down 27% from 2Q 2023).
• Net loss: US$36.9m (loss widened by 21% from 2Q 2023).
• US$0.13 loss per share (further deteriorated from US$0.11 loss in 2Q 2023).

All figures shown in the chart above are for the trailing 12 month (TTM) period

AbCellera Biologics EPS Beats Expectations, Revenues Fall Short

Revenue missed analyst estimates by 26%. Earnings per share (EPS) exceeded analyst estimates by 8.0%.

Looking ahead, revenue is forecast to grow 27% p.a. on average during the next 3 years, compared to a 6.7% growth forecast for the Life Sciences industry in the US.

Performance of the American Life Sciences industry.

The company's shares are down 19% from a week ago.

Risk Analysis

Before you take the next step you should know about the 1 warning sign for AbCellera Biologics that we have uncovered.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.